The Food and Drug Administration yesterday issued a report offering recommendations to address the opioid crisis and the role of analgesic oversight in preventing addiction, overdoses and deaths. Part of the FDA’s Overdose Prevention Framework, the report recommends that the agency: implement recommendations put forward in a 2017 National Academies for Sciences, Engineering, and Medicine report; seek congressional action to strengthen oversight of opioid analgesic approvals and advertising; and increase transparency related to decision-making for opioid analgesics. 
 
Meanwhile, the agency’s independent advisors this week unanimously recommended over-the-counter access to Narcan, a nasal spray used to reverse opioid overdoses. A final decision from FDA is expected by March 29.
 

Headline
A Centers for Disease Control and Prevention report highlights differences in substance use among U.S. high school students. The report, which combined data…
Headline
The Department of Health and Human Services Office for Civil Rights released new guidance on statutory and regulatory requirements under 42 CFR Part 2, which…
Headline
The Health Resources and Services Administration announced Sept. 25 that it awarded $89.3 million in grants to expand access to substance use disorder…
Headline
The Substance Abuse and Mental Health Services Administration Sept. 25 announced that it awarded $247.9 million in grants for services expanding access to…
Headline
The Substance Abuse and Mental Health Services Administration announced Sept. 18 that it awarded $42.3 million in grants to states and territories to support…
Blog
To reduce suicide in the healthcare workforce, hospitals and health systems must create an environment where workers feel safe asking for help.By Susan…